Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $22
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Daniil Gataulin maintains a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and raises the price target from $21 to $22.
May 19, 2023 | 8:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on EyePoint Pharmaceuticals and raises the price target from $21 to $22.
The raised price target by Chardan Capital indicates a positive outlook for EyePoint Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it shows increased confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100